About this trial
Apathy is one of the most common behavioral symptoms of Parkinson's disease. Patients with apathy show diminution in motivation and goal-directed behaviors, which is a fundamental aspect of human functioning, affecting dependency and quality of life. Although apathy is thought to be potentially treatable currently there are no effective treatments for apathy. Given the higher incidence of medical and psychiatric comorbidities, the Veterans Affairs health system represents a unique population for which medication response may be different from the general population. This study aims to evaluate if a medication that has already been proven to be useful in Alzheimer's disease patients with apathy, could be helpful in Parkinson's disease as well as decreasing its debilitating consequences and reducing patients' dependency on caregivers, providing well-deserved relief to patients and their loved ones.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
• Clinically established or probable Parkinson disease according to the Movement Disorders Society Clinical Diagnostic Criteria for Parkinson's Disease
Age 40 or older at the time of screening
Montreal Cognitive Assessment (MoCA) score between 17-30.
Clinical Dementia Rating scale (CDR) lower than 1 and CDR sum of boxes lower than 4.5. The CDR is a numeric scale used to quantify the severity of symptoms of dementia. Using a structured interview protocol, qualified raters assess the subject's cognitive and functional performance in six areas: memory, orientation, judgement, and problem solving, community affairs, home and hobbies, and personal care. Scores are combined to obtain a composite score ranging from 0 through 3. A score between 0 and 1 indicates none or mild symptoms. The individual scores can also be added up, which gives the sum of boxes score.
Disqualifiers
• Meets criteria Major Depressive Episode according to the Diagnostic Statistical Manual of Mental Disorder 5
History of psychotic symptoms due to another illness (i.e., schizophrenia, psychosis in mood disorders, etc.) in the past 2 years
Clinically significant agitation/aggression for which either the frequency of agitation/aggression as assessed by the NPI is 'Very frequently', or the frequency of agitation/aggression as assessed by the NPI is 'Frequently' AND the severity of the agitation as assessed by the NPI is 'Moderate', or 'Marked'
Clinically significant delusions for which either the frequency of delusions as assessed by the NPI is 'Very frequently', or the frequency of delusions as assessed by the NPI is 'Frequently' AND the severity of the delusions as assessed by the NPI is 'Moderate', or 'Marked'
Trial design
Parallel
Treatments tested in this trial
Psychosocial intervention
BehavioralThe counseling session, in which a trained study clinician will counsel the primary caregiver, will take place at each study visit and after the randomization visit. It will last approximately 20-30 minutes. Each counseling session will consist of the following elements: * Review and adjustment of the patient and caregiver supportive care plans * Emotional support and the opportunity to ventilate feelings * Counseling regarding specific caregiving skills * Assistance with problem-solving of specific issues that the caregiver brings to the sessions * Answers to questions regarding the educational materials The educational materials will consist of a copy of the book "The 36-Hour Day" by Nancy L. Mace and Peter V. Rabins. The caregiver also will be provided with 24-hour phone access to the study nurse or physician for assistance with crises that may arise after hours.
Methylphenidate
Drugnorepinephrine and dopamine reuptake inhibitor
Treatment groups
Trial outcomes
Primary outcomes
Apathy Evaluation Scale (AES)
This measure is an 18-item scale initially developed as a method for measuring apathy resulting from brain-related pathology.
Clinical Global Impression of Change (CGIC)
The CGIC is a systematic method, developed for the Alzheimer's disease (AD) setting to assess clinically significant change in a clinical trial as viewed by an independent, skilled, and experienced clinician and has been used as an outcome in Parkinson disease trials
Secondary outcomes
Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog)
This scale was developed specifically to assess cognitive functioning in patients with Alzheimer's disease but has also been used in Parkinson disease.65 It is widely used in clinical trials, and its sensitivity in detecting cognitive changes has been demonstrated in a number of studies. Scores are obtained for orientation, word-list recall, and recognition, object naming, ability to follow simple requests, ideational and constructional praxis, and expressive language. Higher scores indicate worse performance.
Continuous Performance Test (CPT)
The CPT was developed to study vigilance or selective attention. In its original form, letters were presented to participants visually one at a time at a fixed rate. The subjects were to press a lever whenever the target letter X appeared and to not press the lever if any other letter was shown. This is called the X-CPT version, and Beck et al found that this version had adequate classification accuracy. Various modifications of the basic X-CPT have been adopted, including changing the target to a number or picture, or a letter series. The CPT version used for this study will be Conner's CPT Version II. The targets are letters and patients do not respond to the letter X (not-X-CPT).
Trail Making Test (TMT)
The TMT is composed of visual search and sequencing tasks that are heavily influenced by executive functioning (concentration, resistance to distraction, and cognitive flexibility/set-shifting) and attention. These easily administered tasks are extremely sensitive to neuropsychological deficits such as frontal lobe deficits, problems with psychomotor speed, visual search, and sequencing deficits. The Test has two parts: A and B. In Part A, subjects connect numbers in order on a piece of paper as quickly as possible. Part A provides a baseline for processing speed for interpretation of the second part, Part B. For Part B, subjects connect numbers and letters alternately in order such that the connections are 1-A-2-B-3-C and so on. Both parts are timed. Lower times are better.
Neuropsychiatric Inventory (NPI)
The NPI assesses the type and severity of behavioral disturbances in dementia. The inventory evaluates 12 domains of neuropsychiatric symptoms (NPS): apathy, agitation, delusions, hallucinations, depression, euphoria, aberrant motor behavior, irritability, disinhibition, anxiety, sleeping, and eating. Frequency (1 = occasionally, less than once/week; 2 = often, about once per week; 3 = frequently, more than once a week; 4 = very frequently, once or more/day or continuously) and severity (1 = mild, 2 = moderate, 3 = severe) scales in each domain are scored based on responses from an informed caregiver involved in the patient's life. The NPI also includes a 5-point rating used to quantify caregiver distress with the patient's NPS symptoms. To obtain an NPI score for each domain, the severity score and the frequency score are multiplied, and the caregiver distress ratings of each domain are added up.
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: